To hear about similar clinical trials, please enter your email below
Trial Title:
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
NCT ID:
NCT05682703
Condition:
Nasopharyngeal Carcinoma
EBV Infection
Conditions: Official terms:
Epstein-Barr Virus Infections
Carcinoma
Nasopharyngeal Carcinoma
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Other
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Proteomics technology and liquid biopsy
Description:
using proteomics technology and liquid biopsy to investigate the changes of plasma and
urine metabolites by collecting residual blood and urine from routine diagnosis and
treatment or physical examination
Arm group label:
EBV virus infector
Arm group label:
Healthy people
Arm group label:
nasopharyngeal carcinoma patients
Summary:
The transformation process of nasopharyngeal carcinoma is complex, so it is particularly
important to explore the relationship between various disease states on its clinical
pathway. Therefore, we carried out this study to explore the changes of plasma and urine
metabolites at different stages during the occurrence and development of nasopharyngeal
carcinoma.
Criteria for eligibility:
Study pop:
Subjects who met the diagnosis and criteria and were admitted to Nanfang Hospital of
Southern Medical University.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- EBV virus infector: QPCR/EBV antibody, diagnosed as EBV infection patient with
previous infection;
- Nasopharyngeal carcinoma patients:Patients diagnosed as nasopharyngeal carcinoma by
pathological diagnosis (2018 WHO standard);
- Healthy people: Healthy people who have no history of nasopharynx related diseases
or other known diseases that may affect blood lipid/protein metabolism and have been
hospitalized in the Physical Examination Center of Southern Hospital.
Exclusion Criteria:
1. People who have a history of non research related liver diseases or other diseases
known to affect blood metabolism (except for controlled type II diabetes);
2. Have a history of other malignant tumors, except for fully treated basal cell
carcinoma or squamous cell carcinoma and cervical carcinoma in situ;
3. Diseases requiring long-term use of immunosuppressive drugs (including steroids),
including but not limited to congenital or acquired immunodeficiency diseases or
active central nervous system metastatic cancer, active infection or uncontrolled
heart disease;
4. Suffer from other uncontrolled serious diseases at the same time, such as unstable
heart disease requiring treatment, diabetes with unsatisfactory control (fasting
blood glucose>1.5 × Upper limit of normal value), mental illness and severe allergic
history.
5. BMI is less than 18 or more than 25. -
Gender:
All
Minimum age:
18 Years
Maximum age:
70 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Southern medical university
Address:
City:
Guangzhou
Zip:
510515
Country:
China
Status:
Recruiting
Contact:
Last name:
Jian Guan, M.D.
Phone:
86+13632102247
Email:
guanjian5461@163.com
Investigator:
Last name:
Jian Guan, M.D.
Email:
Principal Investigator
Start date:
December 23, 2022
Completion date:
December 20, 2025
Lead sponsor:
Agency:
Nanfang Hospital, Southern Medical University
Agency class:
Other
Source:
Nanfang Hospital, Southern Medical University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05682703
